Write in a clean editor, then format for Substance Use & Addiction Journal in one click — DocuGuru applies the official SAGE template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Substance Use & Addiction Journal is a peer-reviewed journal published by SAGE, covering Opioid Use Disorder Treatment, Substance Abuse Treatment and Outcomes, HIV, Drug Use, Sexual Risk.
| Publisher | SAGE |
|---|---|
| Reference style | Author–year (Harvard) Author–year — (Smith, 2023) in the text Smith, A., Jones, B. and Lee, C. (2023) 'A representative article title', Substance Use & Addiction Journal, 12(3), pp. 45–58.
Formats any DOI in Substance Use & Addiction Journal style. No sign-up. |
| Publishes research in | Opioid Use Disorder Treatment Substance Abuse Treatment and Outcomes HIV, Drug Use, Sexual Risk Prenatal Substance Exposure Effects Health Policy Implementation Science |
| ISSN | 2976-7342 |
| Citation impact (2-yr) | 1.82 |
| h-index | 11 |
| i10-index | 14 |
| Total citations | 673 |
| Top institutions publishing here | Boston University |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
BACKGROUND: Xylazine, an adrenergic alpha-2 agonist increasingly present in the US drug supply, is associated with severe skin ulcers and other harms. Expert knowledge from front-line harm reduction and healthcare professionals is an essential component of evidence-based practice. The purpose of this study is to describe the progression and treatment of xylazine-associated wounds, other xylazine-related…
BACKGROUND: Concerns have been raised that pharmacists sometimes act as barriers to patients with opioid use disorder (OUD) accessing buprenorphine treatment. The present research explores how community pharmacists' endorsement (vs non-endorsement) of stigmatizing beliefs about patients taking buprenorphine relate to intentions, comfort, and decisions regarding dispensing buprenorphine for OUD. In addition, we assessed attitudes toward…
BACKGROUND: Xylazine, an adulterant in local drug supplies, has been detected in approximately 30% of opioid samples submitted for testing in Massachusetts. A better understanding of local risks, harms, and use preferences is needed to combat xylazine-related impacts on local communities. METHODS: Through the STOP-OD Lowell study, we aimed to assess local xylazine awareness through…
BACKGROUND: Increasing naloxone distribution is a high priority means to mitigating opioid overdose rates in the United States. Since a variety of naloxone distribution models exist, with differences in infrastructure and funding between states and health-systems, it is important to review their differences and understand the strengths and barriers to widespread implementation of each model.…
BACKGROUND: Opioid overdose rates continue to rise in the United States while access to treatment options remains limited. The X waiver, which allowed clinicians to prescribe buprenorphine, a medication for opioid use disorder (MOUD), in an outpatient setting, was eliminated in December 2022 with hopes of increasing buprenorphine access. We used a quasi-experimental approach to…
